Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-1.07 · Revenue $5.61M · 8 analysts
Est. EPS $-0.28 · Revenue $940286.00 · 2 analysts
Est. EPS $-0.27 · Revenue $926000.00 · 2 analysts
Est. EPS $-1.05 · Revenue $4.63M · 8 analysts
EPS $-0.25 · Revenue $2.08M
EPS $-0.26 · Revenue $1.30M
EPS $-1.15 · Revenue $6.65M
EPS $-0.27 · Revenue $1.74M
EPS $-0.29 · Revenue $1.91M
EPS $-0.32 · Revenue $1.63M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $6.6M | -51.2% | +60.3% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-136.3M | +26.8% | +3.4% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | -94.1% | +87.8% | +180.2% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -2222.4% | -44.1% | +41.1% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -2051.1% | -50.1% | +39.7% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-112.0M | +9.4% | +24.3% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -1685.8% | -85.9% | +52.8% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 37.6% | +40.5% | +15.4% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 5.79x | -23.6% | -17.2% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $318.9M | -27.6% | -8.7% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.15 vs -1.15 | -0.4% | -0.25 vs -0.28 | +12.3% |
| Revenue Surprise | $6.6M vs $6.6M | +0.4% | $2.1M vs $940286 | +121.4% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | TAHL CINDY | officer: See Remarks | Common Stock | D | 38,800 | $2.46 |
| Aug 4, 2026 | Valamehr Bahram | director, officer: President and CEO | Common Stock | D | 43,947 | $2.46 |
| Jun 12, 2026 | Redmile Group, LLC | director, 10 percent owner: | Stock Option (Right to Buy) | A | 87,900 | $2.06 |
| Jun 12, 2026 | Lee Michael Stewart | director | Stock Option (Right to Buy) | A | 87,900 | $2.06 |
| Jun 12, 2026 | Xu Yuan | director | Stock Option (Right to Buy) | A | 87,900 | $2.06 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Bahram Valamehr | President, Chief Executive Officer & Director | USD 964,700 | — | 1977 | Active |
Cindy R. Tahl | Chief Legal & Compliance Officer and Corporate Secretary | USD 732,700 | Female | 1973 | Active |
Kamal Adawi | CFO & Treasurer | USD 541,973 | Male | 1979 | Active |
Martin Hosking | Head of Research | — | — | — | Active |
Kate Duvall | Corporate Controller | — | Female | — | Active |
Ryan Douglas | Senior Director of Investor Relations & Business Development | — | Male | — | Active |
Jessica Francis | Senior Vice President of Human Resources & Operations | — | Female | — | Active |
Tunde Babalola | Senior Vice President of Technical Operations & Quality | — | — | — | Active |
Yu Cai | Head of Intellectual Property & Assistant General Counsel | — | — | — | Active |
Andrew Henry | Senior Vice President of Clinical Operations | — | Male | 1964 | Active |
Sen. Cynthia Lummis, R-Wyo., discusses the expected CLARITY Act vote, the budget agenda before recess, Congress' August checklist and the Democratic Party's direction after Tuesday's primaries on ‘Mornings with Maria.
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced that on August 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 37,300 shares of the Company's common stock at an exercise price per share of $2.45, which was the closing price per share of the Company's common stock as reported by NASDAQ on July 31, 2026, and (ii) restricted stock units (RSUs) representing 45,300 shares of its common stock to two newly-hired non-executive employees, including the newly-hired employee receiving the non-qualified stock options referenced above. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that preliminary clinical data from the Company's off-the-shelf CAR T-cell product candidate, FT819, will be presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, being held at the Palais des congrès de Montréal in Montréal, Canada on July 8 - 11, 2026.
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that preliminary clinical data from the Company's off-the-shelf CAR T-cell product candidate, FT819, will be presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, being held at the Palais des congrès de Montréal in Montréal, Canada on July 8 - 11, 2026.
